Effectiveness of a multidisciplinary care program for the management of venous thromboembolism in cancer patients: a pilot study
Introduction Treatment of Venous thromboembolism (VTE) in cancer patients is challenging due to higher risk of VTE recurrence or bleeding under anticoagulants. We assessed the effectiveness of a dedicated “Allo-Thrombosis Cancer” multidisciplinary care program (AlloTC-MCP) that incorporated individualized care, regular follow-ups, telephone counselling, and a patient education program. Methods and materials From September 2017 to October 2019, 100 consecutive cancer patients with new VTE onset were enrolled in this observational single-center prospective pilot study and received standard (control group, n = first 50 patients enrolled) or AlloTC-MCP care (n = next 50 patients enrolled) over a 6-month VTE treatment follow-up period. Primary end-point was the percentage of adherence to the International Clinical Practice Guidelines (ITAC-CPGs) at 6 (M6) month follow-up. Results Among the 100 patients with different cancer types (22% genitourinary, 19% breast, 16% gastrointestinal, 15% lymphoma, 11% lung and 17% others), 51 patients (61%) had metastatic disease and 31 (31%) received chemotherapy alone. Main baseline cancer and VTE clinical characteristics did not differ between the 2 groups. Adherence rates to ITAC-CPGs was significantly higher in the AlloTC-MCP group (100% (M0), 72% (M3) and 68% (M6)) compared with the control group (84% (M0), 8% (M3) and 16% (M6)). Quality of Life (QoL) was significantly improved in the AlloTC-MCP group 6 months after inclusion. Conclusion The “AlloTC-MCP” was associated with improved adherence to ITAC-CPGs and merits further expansion..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Journal of thrombosis and thrombolysis - 53(2021), 2 vom: 22. Juli, Seite 417-424 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Benzidia, Ilham [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Anticoagulant |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 |
|---|
| doi: |
10.1007/s11239-021-02512-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2078210145 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2078210145 | ||
| 003 | DE-627 | ||
| 005 | 20230516094121.0 | ||
| 007 | tu | ||
| 008 | 221220s2021 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11239-021-02512-5 |2 doi | |
| 035 | |a (DE-627)OLC2078210145 | ||
| 035 | |a (DE-He213)s11239-021-02512-5-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Benzidia, Ilham |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of a multidisciplinary care program for the management of venous thromboembolism in cancer patients: a pilot study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 | ||
| 520 | |a Introduction Treatment of Venous thromboembolism (VTE) in cancer patients is challenging due to higher risk of VTE recurrence or bleeding under anticoagulants. We assessed the effectiveness of a dedicated “Allo-Thrombosis Cancer” multidisciplinary care program (AlloTC-MCP) that incorporated individualized care, regular follow-ups, telephone counselling, and a patient education program. Methods and materials From September 2017 to October 2019, 100 consecutive cancer patients with new VTE onset were enrolled in this observational single-center prospective pilot study and received standard (control group, n = first 50 patients enrolled) or AlloTC-MCP care (n = next 50 patients enrolled) over a 6-month VTE treatment follow-up period. Primary end-point was the percentage of adherence to the International Clinical Practice Guidelines (ITAC-CPGs) at 6 (M6) month follow-up. Results Among the 100 patients with different cancer types (22% genitourinary, 19% breast, 16% gastrointestinal, 15% lymphoma, 11% lung and 17% others), 51 patients (61%) had metastatic disease and 31 (31%) received chemotherapy alone. Main baseline cancer and VTE clinical characteristics did not differ between the 2 groups. Adherence rates to ITAC-CPGs was significantly higher in the AlloTC-MCP group (100% (M0), 72% (M3) and 68% (M6)) compared with the control group (84% (M0), 8% (M3) and 16% (M6)). Quality of Life (QoL) was significantly improved in the AlloTC-MCP group 6 months after inclusion. Conclusion The “AlloTC-MCP” was associated with improved adherence to ITAC-CPGs and merits further expansion. | ||
| 650 | 4 | |a Venous thromboembolism | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Anticoagulant | |
| 650 | 4 | |a Multidisciplinary care program | |
| 650 | 4 | |a Clinical practice guidelines | |
| 650 | 4 | |a Quality of life | |
| 700 | 1 | |a Crichi, Benjamin |4 aut | |
| 700 | 1 | |a Montlahuc, Claire |4 aut | |
| 700 | 1 | |a Rafii, Hanadi |4 aut | |
| 700 | 1 | |a N’Dour, Arlette |4 aut | |
| 700 | 1 | |a Sebuhyan, Maxime |4 aut | |
| 700 | 1 | |a Gauthier, Hélène |4 aut | |
| 700 | 1 | |a Ait Abdallah, Nassim |4 aut | |
| 700 | 1 | |a Benillouche, Philippe |4 aut | |
| 700 | 1 | |a Villiers, Stéphane |4 aut | |
| 700 | 1 | |a Le Maignan, Christine |4 aut | |
| 700 | 1 | |a Farge, Dominique |0 (orcid)0000-0002-4041-1352 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of thrombosis and thrombolysis |d Springer US, 1994 |g 53(2021), 2 vom: 22. Juli, Seite 417-424 |w (DE-627)18497139X |w (DE-600)1230645-9 |w (DE-576)084448598 |x 0929-5305 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2021 |g number:2 |g day:22 |g month:07 |g pages:417-424 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11239-021-02512-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2021 |e 2 |b 22 |c 07 |h 417-424 | ||